Sacrosidase

Mechanism-of-action class: Enzymatic Activity.

• Sucraid ® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

• Sucraid is contraindicated in patients known to be hypersensitive to yeast, yeast products, glycerin (glycerol), or papain (see WARNINGS).contraindicated

Important Administration Information Administer Sucraid with each meal or snack. Mix Sucraid with cold or room temperature water, milk or infant formula prior to administration. Administration of Sucraid in liquids other than water, milk, or infant formula has not been studied and is not recommended. Do not mix or consume Sucraid with fruit juice. Do not warm or heat the water, milk, or infant formula before or after addition of Sucraid. Administer half of the dose at the beginning of the meal or snack and the other half of the dose during the meal or snack. Recommended Dosage The recommended dosage is: Patients weighing 15 kg and less: 8,500 International Units (1 mL) administered orally with each meal or snack. Patients weighing more than 15 kg: 17,000 International Units (2 mL) administered orally with each meal or snack. Preparation and Administration Instructions for Patients Weighing 15 kg or Less Multiple-Dose Bottle: Using the measuring scoop provided, add 1 scoop of Sucraid (1 mL) to 60 mL of cold or room temperature water, milk, or infant formula. Stir to mix well. Administer half of the mixed Sucraid solution (30 mL) at the beginning of the meal or snack and the other half of the mixed solution (30 mL) during the meal or snack. Do not save any of the mixed Sucraid solution for later use. Rinse the measuring scoop with water. Single-Use Container: Empty the entire contents of the single-use container (2 mL) in 120 mL of cold or room temperature water, milk, or infant formula. Stir to mix well. Divide the mixed Sucraid solution into two separate 60 mL portions.

Severe Hypersensitivity Reactions Severe hypersensitivity reactions, including wheezing, rash, and pruritis, have been reported with administration of Sucraid. Sucraid contains papain, which is associated with hypersensitivity reactions (see DESCRIPTION). A pediatric patient in the clinical trials experienced a hypersensitivity reaction of severe wheezing that required hospitalization. Postmarketing cases of cutaneous hypersensitivity reactions have also been reported. Instruct patients or caregivers to stop Sucraid and seek medical attention if symptoms suggestive of a hypersensitivity reaction occur. Sucraid is contraindicated in patients who have had a known hypersensitivity reaction (see CONTRAINDICATIONS).

The following adverse reactions associated with the use of sacrosidase were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. In clinical studies of up to 54 months duration, a total of 52 patients were treated with Sucraid. The reported adverse reactions (number of patients) were as follows: abdominal pain (4), vomiting (3), nausea (2), diarrhea (2), constipation (2), insomnia (1), headache (1), nervousness (1), and dehydration (1). Hypersensitivity reactions (wheezing, rash, and pruritis) have been reported (see WARNINGS).

Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with Sucraid. Sucraid is not expected to cause fetal harm when administered to a pregnant woman or to affect reproductive capacity. Sucraid should be given to a pregnant woman only if clearly needed.

• Apr 9, 1998BLABLA020772Qol Medcl

1. 1Diarrhoea3119%
2. 2Abdominal Pain3018%
3. 3Nausea1811%
4. 4Abdominal Distension148.5%
5. 5Drug Ineffective148.5%
6. 6Flatulence148.5%
7. 7Headache127.3%
8. 8Product Quality Issue127.3%
9. 9Vomiting116.7%
10. 10Dizziness95.5%
11. 11Insomnia95.5%
12. 12Fatigue84.8%
13. 13Product Taste Abnormal84.8%
14. 14Decreased Appetite74.2%
15. 15Pruritus74.2%

Recent PubMed references pinned to Sacrosidase as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Immobilization of an Invertase Produced by a Bacterium Isolated from the Peach Palm Fruit (Bactris gasipaes): Influence of the Support Material and Biochemical Characterization.
  Journal of agricultural and food chemistry · 2026 · Saraiva LS, Gomes NDCS, Silva JSE, et al.
  PMID 42144900DOI 10.1021/acs.jafc.6c02898
• Transcription factor CitERF36 promotes sucrose accumulation in citrus fruits via activating a sucrose transporter and suppressing a vacuolar invertase.
  The Plant journal : for cell and molecular biology · 2026 · Pang Y, Wang M, Qian W, et al.
  PMID 41921211DOI 10.1111/tpj.70838
• Enhanced fructooligosaccharides synthesis by engineered Trichoderma atroviride β-fructofuranosidase.
  Applied microbiology and biotechnology · 2026 · Narmontaite E, Plou FJ, Fernández-Lobato M, et al.
  PMID 41795023DOI 10.1007/s00253-026-13748-7
• Quantitative all-in-one high-performance thin-layer chromatography-planar start-zone enzyme assay applied for invertase activity.
  Analytica chimica acta · 2026 · Müller I, Englert VH, Morlock GE, et al.
  PMID 41730597DOI 10.1016/j.aca.2026.345213
• Optimization of kestose production by a Saccharomyces cerevisiae invertase exhibiting selective transfructosylation.
  Journal of the science of food and agriculture · 2026 · Baramee S, Tiangpook S, Singkhala A, et al.
  PMID 41681126DOI 10.1002/jsfa.70503
• Structural and mechanistic insights into a novel β-fructofuranosidase from Purpureocillium lilacinum with high transfructosylating activity and an atypical tetrameric assembly.
  International journal of biological macromolecules · 2026 · Narmontaite E, Ruiz-Núñez M, Plou FJ, et al.
  PMID 41617004DOI 10.1016/j.ijbiomac.2026.150552
• Functional redundancy and differentiation of two homologous cell wall invertases, GmCWI11 and GmCWI12, in soybean: modulating seed yield and quality via sugar metabolism.
  Annals of botany · 2026 · Mao T, Wang S, Yu Y, et al.
  PMID 41549388DOI 10.1093/aob/mcag014
• Constitutive OsCIN1 Expression Reprograms Source-Sink Dynamics and Compromises Agronomic Traits in Rice.
  International journal of molecular sciences · 2025 · Nguyen CD, Eom JS, Cho JI, et al.
  PMID 41373626DOI 10.3390/ijms262311471

The 4 most recently updated of 4 ClinicalTrials.gov registrations naming Sacrosidase as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance
  Completed · Phase 2 · Interventional · 25 enrolled · QOL Medical, LLC
  NCT05703009updated 2026-06-08
• 7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels
  Terminated · Phase 4 · Interventional · 312 enrolled · QOL Medical, LLC
  NCT05480761updated 2025-03-20
• Adult Pilot Study for Reference Ranges and Optimal Cut-offs for the Sucrose Challenge Test and Sucrose Breath Test
  Completed · Observational · 211 enrolled · QOL Medical, LLC
  NCT05045495updated 2022-05-24
• A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
  Withdrawn · Phase 4 · Interventional · 0 enrolled · QOL Medical, LLC
  NCT02784067updated 2017-09-25

Frequently asked questions

How does Sacrosidase work?

Mechanism-of-action class: Enzymatic Activity.

What is Sacrosidase used for?

According to FDA labeling, Sacrosidase carries indications including: Sucraid ® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Sacrosidase?

Sacrosidase is classified as Enzymes, Sucrose-specific Enzyme, Enzymatic Activity, Increased Glucose Transport into Cells.

What are the brand names for Sacrosidase?

Sacrosidase is marketed under brand names including Sucraid.

What are the contraindications for Sacrosidase?

Sacrosidase labeling lists contraindications including: Sucraid is contraindicated in patients known to be hypersensitive to yeast, yeast products, glycerin (glycerol), or papain (see WARNINGS).. Always consult the full prescribing information and a clinician.